Project Grant R21AI193880
Award Date 8/11/25
Completion Date 7/31/27
Dollars Obligated $485K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
- This Project Grant award of $448,150 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to explore how the syphilis-causing bacterium Treponema pallidum avoids complement-mediated killing by recruiting the human complement inhibitor Factor H. The goal is to improve understanding of syphilis pathogenesis and identify new control strategies, as syphilis remains a public health concern...
- The University of Connecticut Health Center (UCHC) was awarded a $457,875 Project Grant by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate fundamental aspects of syphilis disease pathogenesis, including nutrient acquisition and environmental sensing by the bacteria Treponema pallidum. The grant, which spans from August 1, 2025 to July 31, 2027, will support research activities to...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $451,956 Project Grant on August 15, 2025 to Baylor College of Medicine under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study the mechanisms by which the syphilis-causing bacterium Treponema pallidum invades and impacts the placenta. The project aims to use novel in vitro models of trophoblast cells and organoids to characterize T. pallidum attachment, growth, and internalization, as well as...
- This Project Grant award of $418,360.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Program (CFDA 93.855), aims to systematically analyze Treponema pallidum gene expression under host infection-related conditions. The central hypothesis is that T. pallidum, the bacterium that causes syphilis, alters its gene expression in response to changes in oxygen concentration, temperature, and host interactions, which enables...
- This $698,349 Project Grant awarded on February 25, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of an "Integrated Multiplexed Diagnostic Assay Targeting Fusion Lipoproteins and Cardiolipin for Detection of Treponemal and Nontreponemal Antibodies in Syphilis Patients." The goal is to create a rapid, point-of-care diagnostic test that can definitively diagnose...
- The University of Washington received a $147,486 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to investigate the role of gamma delta (GD) T cells in controlling Mycobacterium tuberculosis (MTB) infection, which causes tuberculosis (TB). Key objectives include: Evaluating the molecular mechanisms underlying VD1 T cell recognition of mycobacterial...
- This federal Project Grant award of $283,694 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by Dalhousie University to investigate how the syphilis bacterium, Treponema pallidum, interacts with the cervicovaginal epithelial barrier and whether the vaginal microbiome influences susceptibility to T. pallidum infection. The research aims to advance the understanding of syphilis transmission dynamics and...
- The University of Washington (UW) was awarded a $445,338 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID), as part of the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research on "Mechanisms of Age-Related Lung Inflammation in Pulmonary Melioidosis", with a project period from Jul 23, 2025 to Jun 30, 2027. The research aims to investigate resistance to pulmonary melioidosis, a severe tropical...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $301,826 Project Grant on August 20, 2025 to the University of Washington to develop novel agents to eliminate tuberculosis (TB) persisters. The grant, under CFDA 93.855 - Allergy and Infectious Diseases Research, aims to assess the potential of the FDA-approved drug netupitant (NTP) as an anti-persister agent for TB treatment. The University of Washington will use molecular genetic and biochemical strategies to define...
- The University of Washington received a $218,767 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) on February 24, 2025 to conduct a "Single-Cell Transcriptional Atlas of Giardia Encystation" research project. The key objectives are to use single-cell RNA sequencing to build an atlas of gene expression during the cell cycle and differentiation of the Giardia parasite into dormant cyst forms. This...